Enterprise Value

8.456B

Cash

718.3M

Avg Qtr Burn

N/A

Short % of Float

6.44%

Insider Ownership

2.58%

Institutional Own.

99.89%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DEFINITY® Room Temperature Details
Suboptimal echocardiograms

Approved

Quarterly sales

RELISTOR Details
Constipation

Approved

Quarterly sales

PYLARIFY Details
Prostate cancer, Cancer

Approved

Quarterly sales

AZEDRA® (iobenguane I 131) Details
Pheochromocytoma , Paraganglioma , Solid tumor/s

Approved

Quarterly sales

Flurpiridaz F 18 Details
Heart disease, Coronary artery disease

NDA

Acceptance for review

¹⁷⁷Lu-PNT2002 Details
Cancer, Castration-resistant prostate cancer

Phase 3

Data readout

Phase 2

Data readout

¹⁷⁷Lu-DOTA-RM2 Details
Cancer, Prostate cancer

Phase 1/2

Initiation

LNTH-1404 Details
Prostate cancer, Cancer

Failed

Discontinued